Substance / Medication

Phenprocoumon

Overview

Active Ingredient
phenprocoumon
RxNorm CUI
8150

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

30 trials linked to this intervention

30
Total Trials
9
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
Zhang Y, de Boer A, Verhoef T I et al. · J Thromb Haemost · 2017
PMID: 27992949RCT
Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon.
Caduff Good Angela, Nobel Daniel, Krähenbühl Stephan et al. · Swiss Med Wkly · 2013
PMID: 23299853RCT
The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
van Leeuwen Yvonne, Rosendaal Frits R, van der Meer Felix J M · Thromb Res · 2008
PMID: 18407321RCT
Quality of Anticoagulation With Phenprocoumon and Warfarin in Left Ventricular Assist Device Patients: A Multicenter Study.
Schlöglhofer Thomas, Marschütz Angelika, Combs Pamela et al. · ASAIO J · 2023
PMID: 36821448Observational
Resolution of left atrial appendage thrombi: No difference between phenprocoumon and non-vitamin K-dependent oral antagonists.
Biller Katharina, Biller Benedikt, Findeisen Hannes et al. · Clin Cardiol · 2022
PMID: 35373849ObservationalFull text (PMC)
Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
Stankovic Petar, Georgiew Robert, Frommelt Cornelius et al. · J Thromb Thrombolysis · 2019
PMID: 30729376Observational
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.
Ujeyl Mariam, Köster Ingrid, Wille Hans et al. · Eur J Clin Pharmacol · 2018
PMID: 29909576Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Phenprocoumon (substance)
SNOMED CT
59488002
UMLS CUI
C0031444
RxNorm CUI
8150

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
30
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.